

Supplemental data

	PTH RTR based on ULNs provided by Cavalier et al.	Patients number (%) below RTR (<2 ULN of PTH)	Patient number (%) within RTR (2–9 ULN of PTH)	Patient number (%) above RTR (>9 ULN of PTH)
iPTH (2nd generation) assays				
iPTH Elecsys	100–451 pg/mL	21 (19%)	62 (56.4%)	27 (24.5%)
iPTH Architect	129–582 pg/mL	23 (21%)	64 (58.2%)	23 (21%)
iPTH N-tact Liaison	136–613 pg/mL	36 (32.7%)	66 (60%)	8 (7.3%)
iPTH (3rd generation) assays				
Liaison PTH(1-84)	52–232 pg/mL	20 (18.2%)	62 (56.4%)	28 (25.4%)

Supplementary Table 1 Classification of chronic kidney disease (CKD) patients based on KDIGO guideline [see ref. [6] in text] using PTH recommended target range (RTR) based on upper limits of normal (ULN) provided by Cavalier et al. [see ref. [19] in text].